Zepp Health Corporation Sponsored ADR (NYSE:ZEPP - Get Free Report) insider Pengtao Yu sold 5,749 shares of the company's stock in a transaction dated Wednesday, September 23rd. The shares were sold at an average price of $4.30, for a total transaction of $24,720.70. Following the sale, the insider directly owned 102,742 shares of the company's stock, valued at approximately $441,790.60. This represents a 5.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Pengtao Yu also recently made the following trade(s):
- On Thursday, September 24th, Pengtao Yu sold 4,251 shares of Zepp Health stock. The stock was sold at an average price of $4.09, for a total value of $17,386.59.
Zepp Health Price Performance
NYSE:ZEPP opened at $4.12 on Friday. Zepp Health Corporation Sponsored ADR has a one year low of $3.85 and a one year high of $61.85. The stock has a market cap of $60.55 million, a PE ratio of -1.50 and a beta of 1.87. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.70 and a current ratio of 0.90. The stock has a 50 day moving average price of $4.88 and a 200 day moving average price of $8.51.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Monolith Management Ltd acquired a new position in Zepp Health during the 4th quarter worth approximately $3,601,000. Engineers Gate Manager LP raised its position in shares of Zepp Health by 44.4% during the 2nd quarter. Engineers Gate Manager LP now owns 20,917 shares of the company's stock worth $109,000 after acquiring an additional 6,433 shares in the last quarter. AXQ Capital LP purchased a new position in Zepp Health in the second quarter valued at approximately $85,000. Finally, Harvest Fund Management Co. Ltd lifted its position in shares of Zepp Health by 6.7% during the 4th quarter. Harvest Fund Management Co. Ltd now owns 44,800 shares of the company's stock worth $1,207,000 after buying an additional 2,800 shares during the last quarter. 52.61% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
ZEPP has been the subject of several recent analyst reports. Wall Street Zen cut Zepp Health from a "hold" rating to a "sell" rating in a research note on Tuesday, September 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Zepp Health in a research report on Tuesday, September 8th. Finally, Fundamental Research set a $53.01 price objective on shares of Zepp Health and gave the stock a "buy" rating in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $53.01.
Read Our Latest Stock Analysis on ZEPP
Zepp Health Company Profile
(
Get Free Report)
Zepp Health Corporation NYSE: ZEPP is a wearable technology company that develops smart health and fitness devices, along with digital platforms and services designed to help consumers monitor and improve their wellness. Its products collect and analyze information such as activity, sleep, heart rate and other health-related metrics.
The company's principal consumer brand is Amazfit, which offers smartwatches, fitness trackers and related accessories. Zepp Health also operates the Zepp brand of digital health software and services and has introduced products and services focused on areas such as sleep and hearing health.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zepp Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zepp Health wasn't on the list.
While Zepp Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.